BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares.
View BMRN analyst ratings or view top-rated stocks.

19 brokers have issued twelve-month price objectives for BioMarin Pharmaceutical's stock. Their BMRN share price forecasts range from $74.00 to $200.00. On average, they anticipate the company's share price to reach $118.15 in the next twelve months. This suggests a possible upside of 24.0% from the stock's current price.
View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts.

BioMarin Pharmaceutical's stock was trading at $103.49 at the beginning of 2023. Since then, BMRN shares have decreased by 7.9% and is now trading at $95.29.
View the best growth stocks for 2023 here.

BioMarin Pharmaceutical saw a decline in short interest in March. As of March 15th, there was short interest totaling 6,110,000 shares, a decline of 16.1% from the February 28th total of 7,280,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the days-to-cover ratio is presently 4.1 days. Currently, 3.4% of the shares of the stock are short sold.
View BioMarin Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our BMRN earnings forecast.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Monday, February, 27th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.12 by $0.01. The biotechnology company had revenue of $537.54 million for the quarter, compared to the consensus estimate of $533.88 million. BioMarin Pharmaceutical had a net margin of 6.75% and a trailing twelve-month return on equity of 3.73%.

ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Goldman Sachs Future Health Care Equity ETF (GDOC), WisdomTree U.S. Growth & Momentum Fund (WGRO), VictoryShares Nasdaq Next 50 ETF (QQQN) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

BioMarin Pharmaceutical updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided earnings per share guidance of $1.80-$2.05 for the period, compared to the consensus EPS estimate of $1.61. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.58 billion.

228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX).

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Norges Bank (1.48%), Geode Capital Management LLC (1.39%), Parnassus Investments LLC (1.26%), Charles Schwab Investment Management Inc. (0.67%), California Public Employees Retirement System (0.66%) and Legal & General Group Plc (0.63%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere.
View institutional ownership trends.

Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BMRN stock can currently be purchased for approximately $95.29.

BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $17.77 billion and generates $2.10 billion in revenue each year. The biotechnology company earns $141.56 million in net income (profit) each year or $0.74 on an earnings per share basis.

The company employs 3,082 workers across the globe.

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889.